Promising Vaccine Development for Fungal Infections
A new vaccine under development could potentially guard against difficult-to-treat fungal infections affecting nearly a billion people globally, leading to approximately 1.5 million deaths annually.
These infections are increasingly showing resistance to both antibiotics and antifungal treatments, complicating effective treatment options.
Researchers at the University of Georgia have made significant strides in a recent study, demonstrating that their experimental vaccine effectively prevented or lessened the impact of Candida albicans, a multidrug-resistant fungus responsible for up to 95 percent of yeast infections.
Candida albicans is commonly associated with vaginal yeast infections, impacting about three out of four women at least once during their lifetime. The symptoms usually include itching, burning, and discomfort around the vaginal area.
The vaccine, named NXT-2, has been shown to elicit a strong immune response and generate antibodies in female mice, reducing fungal levels by around 50 percent.
The research builds on previous studies where the team confirmed NXT-2’s protective qualities against Candida, as well as other fungi like Pneumocystis and Aspergillus.
These three types of fungi are believed to be responsible for more than 80 percent of fatal fungal infections, including severe pneumonia.
The research team is now gearing up to test the vaccine on women who experience recurrent yeast infections, a condition known as recurrent vulvovaginal candidiasis (RVVC). This condition affects approximately one in ten women throughout their lives and can lead to multiple infections each year.
Current treatment options rely on a single class of drugs, which raises the risk of developing resistance, making future infections harder to manage. Moreover, these medications are often unsuitable for pregnant women and do not prevent subsequent infections.
Lead author Karen Norris, a professor of immunology at UGA, emphasized the need for this advancement, saying, “RVVC is not life-threatening, but it is miserable. This is a huge need.”
Norris also highlighted how the results from these clinical trials could eventually benefit more vulnerable groups, like transplant recipients and cancer patients, who are at greater risk from life-threatening fungi that can cause pneumonia, sepsis, and central nervous system infections.
“I’ve heard from doctors that after patients undergo stem cell transplants for cancer, they might face infections like aspergillosis without adequate treatment options,” Norris explained. “That’s where I believe this vaccine could be incredibly beneficial—especially for those at high risk for severe infections.”
The team’s research, published in June in NPJ Vaccines, tested the NXT-2 vaccine on mice with vulvovaginal candidiasis. The vaccine operates by encouraging the production of antibodies against a protein involved in exporting RNA and proteins. These antibodies attach to fungal pathogens and help destroy the cells.
In the study, one set of mice received the actual vaccine while another group was given a placebo. Results showed that 28 days post-vaccination, the mice that received the vaccine exhibited 50 percent less fungi in their vaginal fluid compared to those that did not. Additionally, vaccinated mice displayed 35 percent less inflammation in their vaginal tissue.
Previous studies from the team indicated that the vaccine also lowered levels of Pneumocystis and Aspergillus fungi, which are associated with serious health issues like Pneumocystis pneumonia and Aspergillosis, infections that can invade the lungs and cause internal complications.
The researchers concluded, “These studies provide supportive evidence for the broad efficacy of NXT-2 and justify its further development as a comprehensive pan-fungal vaccine for local and systemic fungal infections.”
